Small Pharma Inc (OP: DMTTF )
0.0515 -0.0005 (-0.96%) Streaming Delayed Price Updated: 2:58 PM EDT, May 30, 2023 Add to My Watchlist
All News about Small Pharma Inc
Small Pharma's IP Portfolio Grows With Numerous Approved Patent Applications Around The World
May 26, 2023
U.K.-based short-acting psychedelics developer Small Pharma Inc. (OTCQB: DMTTF) has been working hard on securing a proprietary IP throughout North America, Australasia and Europe.
Chief Medical and Scientific Officer, Dr. Carol Routledge, will deliver a poster presentation on data from the Company’s SPL026 Phase IIa clinical trial in patients with Major Depressive Disorder
Major Psychedelics VC & EFT Directors Will Share Valuable Insights At Upcoming Benzinga Event
March 13, 2023
The Benzinga Psychedelics Capital Conference (PCC) is rapidly becoming the place to be for all those interested or involved in the space. In addition to being the place where deals are done, you'll...
Small Pharma Inc: Positive Clinical Data For Major Depressive Disorder, Upcoming Virtual Roundtable
March 08, 2023
Short-acting psychedelics biotech company Small Pharma Inc. (OTCQB: DMTTF) shared positive outcomes from its Phase 2a study of SPL026, the first placebo-controlled trial of the DMT-based short-duration...
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
February 21, 2023
Psychedelics States Reform: Utah, Iowa, Missouri and Oklahoma’s New Bills; Hawaii, Arizona and Washington's Green Lights, New Hampshire's Setback Earlier this week, three bills were introduced and...
Short-Acting Psychedelics: DMT-Based Drug Therapy Gets Tested In New Clinical Trial
February 15, 2023
Psychedelics biotech company Small Pharma Inc. (OTCQB: DMTTF) has dosed the first subject in its first-in-human clinical trial assessing proprietary DMT drug SPL028 paired with supportive therapy.
Race Is On For Psychedelic DMT-Related Compounds, Small Pharma, Inc To Issue Two New Patents
February 01, 2023
After the positive results provided by its clinical trial assessing novel DMT’s effects on patients with Major Depressive Disorder (MDD), psychedelics biotech Small Pharma Inc.
Small Pharma, Inc's Psychedelics For Major Depression Trial Results And Q1 Earnings
January 25, 2023
Short-acting psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF)’s proprietary intravenous (IV) DMT-based drug SPL026 delivered positive topline results in a Phase 2a trial for the treatment of Major...
Small Pharma Reports Fiscal Third Quarter 2023 Highlights
January 25, 2023
Comparing Psychedelics' Administration Routes: Are Intramuscular Injections More Effective Than Intravenous?
January 11, 2023
Short-acting psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF) has dosed the first patient in its Phase 1 clinical trial assessing intramuscular (IM) versus intravenous (IV) administration of its...
Analyzing Psychedelics & Traditional Pharma Interaction: New Clinical Trial Begins Dosing
December 19, 2022
Psychedelics biotech Small Pharma Inc. (OTCQB: DMTTF) confirmed that the first patient has been dosed in its Phase 1b study assessing the interaction between selective serotonin reuptake inhibitors...
The University College London (UCL) is conducting a new research project called “Understanding Neuroplasticity Induced by Tryptamines (UNITy)” aimed at assessing brain changes and neuroplasticity...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following